TY  - JOUR
AU  - Guerra Veloz, María Fernanda
AU  - Belvis Jiménez, María
AU  - Valdes Delgado, Teresa
AU  - Castro Laria, Luisa
AU  - Maldonado Pérez, Belén
AU  - Perea Amarillo, Raúl
AU  - Merino Bohórquez, Vicente
AU  - Caunedo Álvarez, Ángel
AU  - Vilches Arenas, Ángel
AU  - Argüelles-Arias, Federico
PY  - 2019
DO  - 10.1177/1756284819858052
SN  - 1756-283X
UR  - https://hdl.handle.net/10668/26707
T2  - Therapeutic advances in gastroenterology
AB  - Several studies have reported positive efficacy outcomes for patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar. Data from follow-up periods longer than 1 year are still scarce. Here, we assessed the long-term...
LA  - en
KW  - CT-P13
KW  - Crohn’s disease
KW  - ulcerative colitis
TI  - Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data.
TY  - research article
VL  - 12
ER  -